Skip Navigation and Go To Content
  • Graphic of a woman with a nasal passage cross-section overlay, alongside a large illustration of a COVID-19 virus particle

    Dr. Zhiqiang An’s laboratory and his collaborators have developed nasal sprayed antibodies with the potential of the treatment of COVID-19.

  • Extremely magnified image of a mouse tumor with immune cells being blocked from entering the tumor by a barrier of collagen fibers

    Dr. Zhiqiang An and his collaborators reported in a publication in Nature that tumors shed a protein to create barriers that block immune cells.

  • Screenshot of slide presentation presented at the 2022 National Academy of Inventors featuring Dr. Zhiqiang An

    Dr. Zhiqiang An was inducted as a fellow of the National Academy of Inventors at the (NAI) at the academy’s annual meeting in June, 2022 in Phoenix, AZ.

Hancock's headlines :Texas Therapeutics Institute

When the COVID pandemic hit, the Texas Therapeutics Institute sprung into action to develop therapies for patients suffering from the virus. Not only have they developed drugs to help fight COVID, but they are also developing neurological drugs to help combat diseases like Alzheimer's.

Welcome to our lab

Our group focuses on antibody drug resistance mechanisms, biomarkers for therapeutic antibodies, antibody response to viral infection and vaccination, antibody drug discovery targeting human diseases, and therapeutic antibody drug discovery technologies and platforms. During the last ten years, our group and collaborators published over 150 publications in highly competitive journals such as Nature, Nature Communications, Cell Metabolism, Science Advances, Journal of Immunotherapy of Cancer, PNAS, Clinical Cancer Research, Cancer Research, Cancer Immunology Research, Cell Reports, eLife and others. On the translational side, we have advanced 5 first-in-class drug candidates into clinical trials for diseases ranging from acute myeloid leukemia (IO-202), breast cancer bone metastasis (ALMB-0168), solid tumor (IO-108), spinal cord injury (ALMB-0166), and COVID-19 (IGM6268). Five other drug candidates are in preclinical development including PRTH-101 which pioneers a foundational concept of blocking T-cell exclusion in the tumor microenvironment for cancer therapy.

1825 Pressler Sarofim Research Building
Houston, TX 77030-3998 United States